Department of Health Sciences, University of Catanzaro Magna Græcia, Europa Avenue, Germaneto, 88100 Catanzaro, Italy.
Drug Discov Today. 2012 Feb;17(3-4):143-52. doi: 10.1016/j.drudis.2011.10.002. Epub 2011 Oct 13.
Mass spectrometry (MS)-profiling of human bodily fluids is a new approach for the discovery of novel disease biomarkers and, consequently, of new druggable targets. However, the complexity and the high dynamic range of biological samples make the characterization of endogenous peptides and/or proteins a challenging task. To this end, the introduction of new technologies, enabling sample pre-fractionation and/or pre-treatment before MS, could be useful. Progress in the field of nanostructured materials has provided innovative devices, particularly those based on mesoporous silica, which have proved to be successful. The ability to address new emerging material-based MS-profiling platforms will ultimately determine how deeply nanotechnology and proteomics can contribute to improve drug and/or target discovery.
质谱（MS）分析人体体液是发现新型疾病生物标志物的新方法，因此也是发现新的可成药靶标的新方法。然而，生物样本的复杂性和高动态范围使得对内源性肽和/或蛋白质的特征描述成为一项具有挑战性的任务。为此，引入能够在 MS 之前进行样品预分级和/或预处理的新技术可能会有所帮助。纳米结构材料领域的进展提供了创新设备，特别是基于介孔硅的设备，这些设备已被证明是成功的。能够解决新兴的基于材料的 MS 分析平台的能力最终将决定纳米技术和蛋白质组学在多大程度上有助于改善药物和/或靶标的发现。
